Namenda vs. Namzaric

• Are Namzaric and Namenda the Same Thing?
• What Are Possible Side Effects of Namenda?
• What Are Possible Side Effects of Namzaric?
• What Is Namenda?
• What Is Namzaric?
• What Drugs Interact with Namenda?
• What Drugs Interact with Namzaric?
• How Should Namenda Be Taken?
• How Should Namzaric Be Taken?

Namenda (memantine hydrochloride) and Namzaric (amphetamine and dextroamphetamine salts) are used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy.

Namenda is used off-label for ADHD. It is approved to treat moderate to severe Alzheimer's type dementia.

Namenda and Namzaric belong to different drug classes. Namenda is an orally active NMDA receptor antagonist and Namzaric is an amphetamine.

Side effects of Namenda and Namzaric that are similar include dizziness, nausea, vomiting, diarrhea, constipation, loss of appetite, weight loss, headache, fast heart rate, weakness, or anxiety.

Side effects of Namenda that are different from Namzaric include tiredness, body aches, joint pain, swelling in your hands or feet, easy bruising or bleeding, aggression, skin rash, redness or swelling of or around your eyes, or urinating more than usual.

Side effects of Namzaric that are different from Namenda include nervousness, restlessness, excitability, irritability, agitation, fear, tremor, blurred vision, sleep problems (insomnia), dry mouth or unpleasant taste in the mouth, stomach pain, fever, hair loss, loss of interest in sex, impotence, difficulty having an orgasm, increase blood pressure, and heart palpitations.

Both Namenda and Namzaric may interact with sodium bicarbonate (Alka-Seltzer) or diuretics (water pills).

Namenda may also interact with cimetidine, nicotine, ranitidine, quinidine, antiviral medications, cold or cough medicines containing dextromethorphan, medicines to treat glaucoma, or oral diabetes medicines containing metformin.

Namzaric may also interact with heart or blood pressure medications, cold or allergy medicines (antihistamines), acetazolamide, chlorpromazine, ethosuximide, haloperidol, lithium, meperidine, methenamine, phenytoin, phenobarbital, reserpine, ammonium chloride, ascorbic acid (vitamin C), potassium phosphate, antacids, potassium citrate, sodium citrate and citric acid, sodium citrate and potassium, stomach acid reducers, or antidepressants.

Common side effects of Namenda include:

• drowsiness,
• dizziness,
• constipation,
• nausea,
• vomiting,
• loss of appetite,
• dry mouth, or
• warmth or redness under the skin.

Tell your doctor if you have any serious side effects of Namenda including:

• increased blood pressure,
• the inability to fully empty the bladder (urinary retention),
• sinus pain,
• dry mouth,
• sore throat,
• diarrhea,
• constipation,
• bloating,
• memory issues,
• headache,
• joint pain,
• dizziness,
• blurred vision,
• tired feeling,
• stomach pain and,
• nausea.

Tell your doctor if you experience serious side effects of Namenda including

• fast or pounding heartbeats,
• pain or burning when you urinate,
• difficulty urinating,
• trouble emptying your bladder,
or
• dangerously high blood pressure (severe headache,
• buzzing in your ears,
• anxiety,
• confusion,
• chest pain,
• shortness of breath,
• uneven heartbeats,
• seizures).

Common side effects of Namzaric include:

• headache
• diarrhea
• dizziness
• flu symptoms
• anxiety
• high or low blood pressure
• constipation
• abdominal pain
• vomiting
• weight gain
• back pain
• sleepiness
• depression
• aggression, and
• urinary incontinence

Namenda (mirabegron) is a beta-3 adrenergic agonist used to treat overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.

Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) is a combination of an orally active NMDA receptor antagonist, and a reversible inhibitor of the enzyme acetylcholinesterase, used to treat moderate to severe dementia of the Alzheimer's type in patients stabilized on memantine hydrochloride and donepezil hydrochloride.

Namenda may interact with metoprolol, desipramine, or digoxin.

Namzaric may interact with NMDA antagonists, anticholinergics, succinylcholine, similar neuromuscular blocking agents, or cholinergic agonists.

Namenda is available as a 10 mg tablet and a solution (30 mg per ml) for intravenous (IV) or intramuscular (IM) administration. Namenda solution is administered as a single 15- to 60-mg dose once every 6 hours not to exceed 60 or 120 mg a day. The recommended oral dose is one to two Namenda tablets initially followed by one tablet every 4-6 hours, not to exceed 40 mg daily. Namenda should not be used for more than 5 days.

Namzaric may interact with NMDA antagonists, anticholinergics, succinylcholine, similar neuromuscular blocking agents, or cholinergic agonists.